Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.41 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.39 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.39 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL374925 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP3A4CASP1RECQL | |
| Hydrochloric Acid SCHEMBL30469303 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP3A4CASP1RECQL | |
| SCHEMBL29647628 | 0.98 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP3A4CASP1RECQL | |
| SCHEMBL374790 | 0.98 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP3A4CASP1RECQL | |
| Water SCHEMBL28687154 | 0.95 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP3A4CASP1RECQL | |
| 2-Fluoroethanaminium SCHEMBL4459052 | 0.86 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP3A4CASP1RECQL | |
| Sulfuric Acid SCHEMBL9277102 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP3A4CASP1RECQL | |
| SCHEMBL19667909 | 0.86 | CYP3A4 (0.54) | ALDH1A1TSHRCYP3A4CASP1RECQL | |
| SCHEMBL3780784 | 0.85 | MAOA (0.56) | ALDH1A1TSHRCYP3A4CASP1RECQL | |
| SCHEMBL11503532 | 0.83 | CYP3A4 (0.52) | ALDH1A1TSHRCYP3A4CASP1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115655837-A | Ammonium salt solution, ferric diamine-Alisine blue staining solution and application thereof | 河南赛诺特生物技术有限公司 | 2023-01-31 | — | — | CN | claimed |
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | claimed |
| EP-0558104-B1 | 1,5-Benzodiazepine derivatives and their use in medicine | GLAXO WELLCOME SPA (IT) | 1998-07-29 | — | — | EP | claimed |
| CN-115655837-B | Ammonium salt solution, high-iron diamine-aliskirin blue staining solution and application thereof | 河南赛诺特生物技术有限公司 | 2025-09-30 | — | — | CN | disclosed |
| US-20240246980-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2024-07-25 | — | — | US | disclosed |
| WO-2024092222-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-3817811-B1 | TRIAZOLE BENZAMIDE DERIVATIVES AS GPR142 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2024-04-03 | — | — | EP | disclosed |
| CN-113842451-B | FAM3D protein and medical application of polynucleotide for encoding same | 北京大学 | 2023-09-19 | — | — | CN | disclosed |
| CN-115655837-A | Ammonium salt solution, ferric diamine-Alisine blue staining solution and application thereof | 河南赛诺特生物技术有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115655837-A | Ammonium salt solution, ferric diamine-Alisine blue staining solution and application thereof | 河南赛诺特生物技术有限公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-3558964-B1 | 4-AMINO-2-PYRIDO-BICYCLIC PYRIMIDINES AND USE THEREOF AS TOPOISOMERASE II INHIBITORS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2022-05-04 | — | — | EP | disclosed |
| US-4824951-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-04-25 | — | — | US | disclosed |
| US-4772600-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC | A. H. ROBINS COMPANY, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0255217-A1 | Fused imidazoheterocyclic compounds | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-02-03 | — | — | EP | disclosed |
| US-4675319-A | Antianaphylactic and antibronchospastic piperazinyl-(N-substituted phenyl)carboxamides, compositions and use | RECORDATI S. A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1987-06-23 | — | — | US | disclosed |
| CN-86105641-A | The method for preparing antianaphylaxis and antibronchospasm of N-dibenzyl-diazacyclo alkyl-alkyl-anilide | — | 1987-04-01 | — | — | CN | disclosed |
| EP-0207901-A1 | Antianaphylactic and antibronchospastic N-benzhydryldiazacycloalkylalkananilides | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1987-01-07 | — | — | EP | disclosed |
| EP-0077209-B1 | NITROGEN-CONTAINING PROSTACYCLIN ANALOGUES AND COMPOSITIONS CONTAINING THEM | THE UPJOHN COMPANY (US) | 1987-01-07 | — | — | EP | disclosed |
| US-4496742-A | Analogs of 5,6-dihydro PGI2 | THE UPJOHN COMPANY (US) | 1985-01-29 | — | — | US | disclosed |
| EP-0077209-A1 | Nitrogen-containing prostacyclin analogues and compositions containing them | THE UPJOHN COMPANY (US) | 1983-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246980-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | MRGPRX1, MRGPRX2, MRGPRX4 | SIGMAR1 746/4885CA2 1162/4885MAOA 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.